Translational Research Initiative for Pain and Neuropathy (TRIPN) hosts inaugural research symposium
On Tuesday, November 5, the VCU Translational Research Initiative for Pain and Neuropathy (TRIPN) hosted its inaugural symposium showcasing the latest developments in pain and neuropathy research.
VCU Massey Cancer Center partners with Children’s Hospital of Richmond at VCU to offer CAR T-cell therapy to children
This summer, VCU Massey Cancer Center in partnership with Children’s Hospital of Richmond at VCU (CHoR) became a certified treatment center for Novartis’ KYMRIAH, an FDA-approved CAR T-cell therapy for acute lymphoblastic leukemia in children and young adults. Massey was the first in Virginia to offer an FDA-approved CAR T-cell therapy last year with Gilead’s YESCARTA, and the addition of KYMRIAH is another milestone in providing expanded access to cutting-edge cellular immunotherapies.
Q&A with Dr. Kandace McGuire on new mammography guidelines from The American Society of Breast Surgeons
This week, The American Society of Breast Surgeons (ASBrS) issued new mammogram guidelines that recommend women of average risk of breast cancer should begin annual screening mammograms starting at age 40 and that women over 25 should undergo a formal risk assessment for breast cancer. Kandace McGuire, M.D., chief of breast surgery and director of the Breast Cancer Collaborative Care Clinic at VCU Massey Cancer Center, supports these new guidelines even though they differ from those suggested by the US Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS).
In this Q&A, Dr. McGuire discusses the new guidelines and the reasons she supports them.
Cancers are a complex of family of diseases that call for equally diverse treatments. Depending on the diagnosis, treatment programs may call upon multiple specialists and several types of therapies. All of the tests, appointments and medical jargon can easily overwhelm patients—that’s where nurse navigators come in.
Thomas Bland learned only learned he had an aggressive form of kidney cancer after he was rushed to the hospital for injuries sustained during a car accident. After standard therapy failed, his doctor turned to a form of immunotherapy known as a checkpoint inhibitor. Now, Mr. Bland is the first stage 4 sarcomatoid kidney cancer patient to be cured of the disease.